G Bacci

Summary

Affiliation: Istituti Ortopedici Rizzoli
Country: Italy

Publications

  1. doi Diagnosis and prognosis for the Ewing family of tumors
    Emanuela Palmerini
    Istituto Ortopedico Rizzoli, Department of Musculoskeletal Oncology, Via Pupilli 1, 40136 Bologna, Italy 39 051 6366 829 39 051 6366 277
    Expert Opin Med Diagn 3:445-52. 2009
  2. ncbi Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 90:478-84. 2004
  3. ncbi The role of surgical margins in treatment of Ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Radiat Oncol Biol Phys 65:766-72. 2006
  4. ncbi Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients
    Gaetano Bacci
    Division of Chemotherapy, Institute Ortopedico Rizzoli, Bologna, Italy
    Cancer 106:2701-6. 2006
  5. ncbi Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute
    G Bacci
    Section of Chemotherapy, Rizzoli Orthopaedic Institute, Bologna, Italy
    Eur J Cancer 38:2243-51. 2002
  6. ncbi Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients
    G Bacci
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Bone Joint Surg Br 88:1071-5. 2006
  7. ncbi High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study
    G Bacci
    Sezione di Chemioterapia, Instituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 14:198-206. 2002
  8. ncbi High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation
    Gaetano Bacci
    Department of Chemotherapy, Rizzoli Orthopedic Institute, Bologna, Italy
    J Pediatr Hematol Oncol 24:27-30. 2002
  9. ncbi Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases
    Gaetano Bacci
    Sections of Chemotherapy, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Radiat Oncol Biol Phys 67:505-11. 2007
  10. ncbi Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute
    Gaetano Bacci
    Sezione di Chemioterapia, Istituti Ortopedici Rizzoli, I 40136 Bologna, Italy
    Oncol Rep 9:171-5. 2002

Detail Information

Publications128 found, 100 shown here

  1. doi Diagnosis and prognosis for the Ewing family of tumors
    Emanuela Palmerini
    Istituto Ortopedico Rizzoli, Department of Musculoskeletal Oncology, Via Pupilli 1, 40136 Bologna, Italy 39 051 6366 829 39 051 6366 277
    Expert Opin Med Diagn 3:445-52. 2009
    ..The molecular characterization of chromosomal translocations has an important role in the diagnosis of EFT...
  2. ncbi Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 90:478-84. 2004
    ..The study evaluated the correlation between pretreatment serum lactate dehydrogenase (LDH) levels with the stage of disease and its clinical prognostic value...
  3. ncbi The role of surgical margins in treatment of Ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Radiat Oncol Biol Phys 65:766-72. 2006
    ..To evaluate the importance of surgical margins for local and systemic control of Ewing's sarcoma family tumors (ESFT)...
  4. ncbi Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients
    Gaetano Bacci
    Division of Chemotherapy, Institute Ortopedico Rizzoli, Bologna, Italy
    Cancer 106:2701-6. 2006
    ....
  5. ncbi Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute
    G Bacci
    Section of Chemotherapy, Rizzoli Orthopaedic Institute, Bologna, Italy
    Eur J Cancer 38:2243-51. 2002
    ....
  6. ncbi Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients
    G Bacci
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Bone Joint Surg Br 88:1071-5. 2006
    ....
  7. ncbi High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study
    G Bacci
    Sezione di Chemioterapia, Instituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 14:198-206. 2002
    ..On the basis of this study, in March 1997 the Italian and Scandinavian Sarcoma Groups started a new protocol for osteosarcoma of the extremities...
  8. ncbi High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation
    Gaetano Bacci
    Department of Chemotherapy, Rizzoli Orthopedic Institute, Bologna, Italy
    J Pediatr Hematol Oncol 24:27-30. 2002
    ....
  9. ncbi Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases
    Gaetano Bacci
    Sections of Chemotherapy, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Radiat Oncol Biol Phys 67:505-11. 2007
    ..Evaluate treatment and outcome of 20 patients with radioinduced osteosarcoma (RIO). Because of previous primary tumor treatment, RIO protocols were different from others we used for non-RIO...
  10. ncbi Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute
    Gaetano Bacci
    Sezione di Chemioterapia, Istituti Ortopedici Rizzoli, I 40136 Bologna, Italy
    Oncol Rep 9:171-5. 2002
    ....
  11. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Cancer 37:2030-9. 2001
    ..These results did not differ from those achieved in our previous study (IOR/OS-3) in which IFO was used only postoperatively in poor responders...
  12. ncbi Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 28:774-80. 2006
    ..0.8%, P<0.009). Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented...
  13. ncbi Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years
    Gaetano Bacci
    Department of Chemotherapy, Rizzoli Orthopaedic Institute, Bologna, Italy
    Cancer 109:780-6. 2007
    ..The clinical and pathologic features of 46 patients 40 to 60 years old with Ewing sarcoma family tumor (ESFT) diagnosed at the authors' institute between 1972 and 2000 were reviewed...
  14. ncbi Current treatment of high grade osteosarcoma of the extremity: review
    G Bacci
    Dept of Musculoskeletal Oncology of the Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 13:235-43. 2001
    ..These advances are mainly due to the development of effective adjuvant and neoadjuvant chemotherapy regimens. This review reports on the progress and controversies in the treatment of osteosarcoma...
  15. ncbi Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy
    G Bacci
    Service of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, I 40136 Bologna, Italy
    Oncol Rep 8:883-8. 2001
    ....
  16. ncbi Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis
    Gaetano Bacci
    Chemotherapy Unit, Department of Musculoskeletal Oncology of the Rizzoli Orthopedic Institute, Bologna, Italy
    J Pediatr Hematol Oncol 25:118-24. 2003
    ..64% and 44% vs. 69%). Thus, despite associated chemotherapy, the outcome of ES localized in the pelvis remains poor, and new innovative methods for the treatment of this tumor are needed...
  17. ncbi Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999
    G Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Eur J Surg Oncol 32:974-9. 2006
    ..Evaluation of pattern of recurrences of 290 patients with an Ewing's sarcoma family tumor (ESFT), who relapsed after adjuvant or neoadjuvant chemotherapy...
  18. ncbi Primary high-grade osteosarcoma: comparison between preadolescent and older patients
    Gaetano Bacci
    Department of Chemotherapy, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 27:129-34. 2005
    ..89%), and good histologic response to preoperative treatment (65% vs. 63%) were essentially the same. The authors concluded that there is no need to employ different therapies for the two groups...
  19. ncbi Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992
    G Bacci
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Eur J Cancer 40:73-83. 2004
    ..We conclude that since local or systemic relapses, treatment-complications and second malignancies are more common after 5 years or more from the beginning of treatment; a long-term follow-up is mandatory for patients with ES...
  20. ncbi Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy
    Gaetano Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, I 40136 Bologna, Italy
    Oncol Rep 11:111-20. 2004
    ..Our results indicate that surgery should always be considered in the local treatment of ES of the extremities. Postoperative radiation therapy must be added in case of inadequate surgical margins...
  21. ncbi Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Eur J Cancer 41:2079-85. 2005
    ..Nonetheless, since they represent more than 70% of all osteosarcomas, we conclude that chemotherapy-induced necrosis has a significant prognostic value, regardless of the type of chemotherapy performed after surgery...
  22. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzolo, Bologna, Italy
    J Pediatr Hematol Oncol 25:845-53. 2003
    ....
  23. ncbi Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 14:1654-9. 2003
    ..Many papers have reported the results achieved with combined therapy for Ewing's tumors, but little is known about the treatment and outcome of those 30-40% of patients who relapse...
  24. ncbi Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999
    Gaetano Bacci
    Department of Chemotherapy, Musculoskeletal Oncology at Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 27:517-20. 2005
    ..Based on this, postoperative radiotherapy should be avoided when surgery with adequate margins is feasible...
  25. ncbi Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico, Rizzoli, Bologna, Italy
    Acta Oncol 44:748-55. 2005
    ..The complete removal of the recurrence is essential for outcome, while the role of the association of second-line chemotherapy remains to be defined...
  26. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide
    G Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 14:1126-34. 2003
    ..Currently, little is known about patients with metastatic disease at presentation...
  27. ncbi Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy
    Gaetano Bacci
    Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Cancer 41:2836-45. 2005
    ..However, since local or systemic relapses, myocardiopathies and a second malignancy are possible even 5 or more years since the beginning of treatment, a long-term follow-up is recommended...
  28. ncbi Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy
    Gaetano Bacci
    Department of Musculoskeletal Oncology, Division of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, I 40136 Bologna, Italy
    Oncol Rep 10:851-7. 2003
    ..However, if "rescue" treatment is started early, the consequent morbility is tolerable and these patients can be rescued using only HDLV, without the need for extracorporeal removal...
  29. ncbi Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor
    Gaetano Bacci
    Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Cancer 97:3068-75. 2003
    ..In primary central high-grade osteosarcoma, a number of distinct subtypes have been identified, but little is known about the response to chemotherapy...
  30. ncbi Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution
    Gaetano Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Cancer 106:1154-61. 2006
    ..The evaluation variables influencing systemic and local recurrence and final outcome are extremely important in defining risk-adapted treatments for patients with nonmetastatic osteosarcoma of the extremity...
  31. ncbi No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma
    Gaetano Bacci
    Chemotherapy Research of the Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Anticancer Drugs 17:411-5. 2006
    ..Thus, increasing the dose of MTX increases the MTX serum peaks, but does not correlate with the histologic response of the tumor...
  32. ncbi Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Orthop Scand 72:167-72. 2001
    ..01) in the TO group. We conclude that TO, once considered a lethal tumor, seems to be even more sensitive to chemotherapy than conventional osteosarcoma, and that most of these patients may be cured without amputation...
  33. ncbi Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Orthop 77:938-43. 2006
    ....
  34. ncbi A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Surg Oncol 27:98-104. 2001
    ..Our experience of pre-operative intraarterial (i.a.) vs intravenous (i.v.) infusion of cisplatinum (CDP) in a multiagent neo-adjuvant chemotherapy for osteosarcoma of the extremity is reported...
  35. ncbi Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998
    Gaetano Bacci
    Chemotherapy, Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Oncol 45:469-75. 2006
    ..Criteria to stratify patients according to the risk of local or systemic relapse should not be based on a single prognostic factor, but should include all the variables that showed prognostic significance...
  36. pmc Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution
    Gaetano Bacci
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
    Eur Spine J 18:1091-5. 2009
    ..We concluded that regardless of the type of local treatment even when associated with neoadjuvant therapy, ESFT in the spine and sacrum has a poor outcome and prognosis is significantly worse than that of primary ESFT in other sites...
  37. ncbi Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy
    Gaetano Bacci
    Department of Musculoskeletal Oncology of the Rizzoli Orthopaedic Institute, Bologna, Italy
    Acta Orthop Scand 74:449-54. 2003
    ....
  38. doi Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience
    Gaetano Bacci
    Chemotherapy Unit, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 30:908-12. 2008
    ..20%). The authors conclude that there does not seem to be any indication to treat preadolescent primary high-grade nonmetastatic osteosarcoma patients by alternative and/or more aggressive therapies...
  39. doi High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Surg Oncol 98:415-20. 2008
    ..Between 1986 and 2001, 162 patients with extremity osteosarcoma and lung metastases at presentation, were treated by neoadjuvant chemotherapy, simultaneous resection of primary and, when feasible, secondary lesions followed by chemotherapy...
  40. doi Spontaneous regression of lung metastasis from osteosarcoma: a case report
    Gaetano Bacci
    Division of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 30:90-2. 2008
    ..The patient was followed up every 3 months and a spontaneous regression of the lesion was documented. Seven years after the diagnosis of lung metastases, no pulmonary nodules or other signs of relapse are present...
  41. ncbi Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment
    G Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 18:2037-40. 2007
    ..Post 5-year follow-up for these patients was 9.7 years (5.5-29 years)...
  42. ncbi Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Surg Oncol 96:118-23. 2007
    ..Indications and contraindications for limb salvage versus amputation for local treatment of osteosarcoma of the extremity are still controversial...
  43. ncbi Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours
    G Bacci
    Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Bone Joint Surg Br 89:1229-33. 2007
    ..We concluded that in ESFT the site, the serum level of lactic dehydrogenase, fever, and the interval between the onset of symptoms and diagnosis are indicators of tumours having a particularly aggressive metastatic behaviour...
  44. ncbi Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report
    G Bacci
    Service of Chemotherapy, Laboratory of Pathology, Fifth Service of Orthopedic Surgery, and Laboratory of Oncologic Research, Department of Musculoskeletal Oncology, I F Goidanich of the Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:4016-27. 2000
    ..To provide an estimate of long-term prognosis for patients with osteosarcoma of the extremity treated in a single institution with neoadjuvant chemotherapy and observed for at least 10 years...
  45. ncbi Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol
    G Bacci
    Chemotherapy Division, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 13:93-9. 2001
    ..These results, however, are no better than those achieved in our previous study IOR/OS-3a, in which only poor responder patients received ifosfamide during the postoperative treatment...
  46. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Orthop 78:377-84. 2007
    ....
  47. ncbi Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience
    G Bacci
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
    Oncol Rep 7:1129-33. 2000
    ....
  48. ncbi Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli
    G Bacci
    Departments of Musculo Skeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:4-11. 2000
    ..The identification of prognostic factors in patients with nonmetastatic Ewing's sarcoma could allow the use of risk-adapted therapeutic strategies of treatment...
  49. ncbi Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 9:293-9. 1997
    ..The results of the present study seem to indicate that, in spite of a usually poor histologic response to preoperative treatment, neoadjuvant chemotherapy is very effective also in MFH of bone...
  50. ncbi Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli
    G Bacci
    Departments of Chemotherapy and Pathology and Fifth Department of Orthopedic Surgery, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:885-92. 2000
    ..The results achieved in 44 patients with nonmetastatic peripheral neuroectodermal tumor (PNET) of bone treated with neoadjuvant chemotherapy are reported...
  51. ncbi Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Oncol 37:41-8. 1998
    ..Therefore, until new effective drugs are found, expertise in using the four known drugs may improve cure rate and help to avoid amputation in almost all patients...
  52. ncbi Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy
    G Bacci
    Chemotherapy Division, Rizzoli Orthopedic Institute, Bologna, Italy
    J Chemother 10:69-76. 1998
    ....
  53. ncbi No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies
    G Bacci
    Department of Internal Medicine and Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 5:247-57. 1993
    ..These findings stress the need to find more effective chemotherapeutic regimens for the associated treatment of this tumor...
  54. ncbi Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity
    S Ferrari
    Department of Chemotherapy, Istituto Ortopedico Rizzoli Bologna, Italy
    J Chemother 10:484-91. 1998
    ..The present study suggests the importance of early use of ifosfamide in the treatment of patients with non metastatic Ewing's sarcoma of the extremity...
  55. ncbi Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma
    G Bacci
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Acta Oncol 37:671-6. 1998
    ..The analysis of event-free survival in 158 patients with a 4-year minimum follow-up confirmed that histological response to preoperative chemotherapy is a reliable predictor of outcome in Ewing's sarcoma...
  56. ncbi Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for telangiectatic osteogenic sarcoma of the extremities
    G Bacci
    Department of Internal Medicine and Medical Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 1:190-6. 1989
    ..Employing neoadjuvant chemotherapy a high percentage of patients with TOS can be cured and in most of them, limb sparing surgery is possible and safe...
  57. ncbi Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 4:189-95. 1992
    ..A longer follow-up is necessary to establish if this improved good response rate achieved with IA CDDP will lead to an improved cure rate.(ABSTRACT TRUNCATED AT 250 WORDS)..
  58. ncbi Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 7:230-9. 1995
    ..Prolongation of time relapsed after more effective regimens of adjuvant and neoadjuvant chemotherapy should be considered when evaluating the preliminary results of new chemotherapy protocols...
  59. ncbi The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively
    G Bacci
    Servizio Medicina Interna, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 2:127-35. 1990
    ....
  60. ncbi Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases
    A Longhi
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 13:324-30. 2001
    ..This homogeneity supports the thesis that in synchronous multifocal osteosarcoma the tumors are not multicentric in origin but represent bone-to-bone metastases from a monocentric tumor...
  61. ncbi Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy
    G Bacci
    Department of Chemotherapy, Rizzoli Orthopaedic Institute, Bologna, Italy
    J Bone Joint Surg Br 84:88-92. 2002
  62. ncbi Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies
    G Bacci
    Department of Chemotherapy, Istituto Rizzoli, Bologna, Italy
    J Chemother 5:237-46. 1993
    ....
  63. ncbi Adjuvant and neoadjuvant chemotherapy in osteosarcoma
    G Bacci
    Sezione di Chemioterapia, Istituti Ortopedici Rizzoli, Bologna
    Chir Organi Mov 86:253-68. 2001
    ....
  64. doi Local and systemic control of Ewing's bone sarcoma family tumors of the ribs
    Antonio Briccoli
    Unit of General Surgery, Istituto Ortopedico Rizzoli, Bologna 40136, Italy
    J Surg Oncol 100:222-6. 2009
    ..A retrospective analysis of the results and relapse pattern was evaluated in 34 patients with Ewing's family bone tumors (EFBT) treated at Rizzoli Institute with neoadjuvant chemotherapy between 1983 and 2003...
  65. ncbi Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide
    S Ferrari
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Anticancer Drugs 10:25-31. 1999
    ..We conclude that a chemotherapy regimen with high-dose IFO in young adults pretreated with MTX, cisplatin and standard-dose IFO is feasible with a mild, usually reversible, nephrotoxicity...
  66. ncbi Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen
    S Ferrari
    Sezione di Chemioterapia dei Tumori dell Apparato Locomotore, Instituti Ortopedici Rizzoli, Bologna, Italy
    J Chemother 5:135-41. 1993
    ..This is probably independent from the MTX because no significant preoperative MTX serum levels between good and partially responding patients were observed.(ABSTRACT TRUNCATED AT 250 WORDS)..
  67. ncbi Primary chemotherapy and delayed surgery for malignant fibrous histiocytoma of bone in the extremity
    G Bacci
    Centro di Chemioterapia Oncologica, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 76:537-42. 1990
    ....
  68. doi Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
    I Scionti
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 19:1500-8. 2008
    ..C-MYC and DHFR protein levels at diagnosis were assessed by immunohistochemistry on series of patients treated with either a MTX-based protocol (IOR/OS-1; 72 patients) or with a standard four-drug regimen (ISG/SSG 1; 61 patients)...
  69. ncbi Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study
    G Bacci
    Sezione di Chemioterapia dei Tumori Ossei, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 8:70-81. 1996
    ..In the IA group, however, there was only one local recurrence vs 5 in the IV group. The IA infusion of CDP is more active on the primary tumor than the IV infusion...
  70. ncbi Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: a comparison of results obtained in single-institution and multicenter trials
    G Bacci
    Dipartimento di Oncologia Muscoloscheletrica, Istituti Ortopedici Rizzoli, Bologna, Italia
    Chir Organi Mov 89:283-92. 2004
    ..Based on these differences, the authors conclude that it would be opportune to direct patients with osteosarcoma of the extremities to the best centers that each year treat large numbers of patients with musculoskeletal tumors...
  71. ncbi Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities
    G Bacci
    Chemotherapy Department, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 6:204-10. 1994
    ....
  72. ncbi Metastatic patterns in osteosarcoma
    G Bacci
    Bone Tumor Center, Istituto Ortopedico Rizzoli, Bologna, Italia
    Tumori 74:421-7. 1988
    ..This alteration in metastatic pattern due to adjuvant chemotherapy is important because it allows surgical resection of pulmonary metastases in a larger number of patients (51% vs 29%)...
  73. ncbi Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions)
    G Bacci
    Sezione Chemioterapia Tumori Ossei, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 78:200-6. 1992
    ..The data suggest that a very effective neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities gives disappointing results in osteosarcoma of the extremities which is metastatic at presentation...
  74. ncbi Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities
    P Picci
    Department of Pathology, Rizzoli Orthopedic Institute, Bologna, Italy
    J Clin Oncol 15:1553-9. 1997
    ..This study was performed to assess the prognostic value of the proposed histopathologic method to evaluate the response of the primary tumor to preoperative chemotherapy in Ewing's sarcoma...
  75. ncbi Primary lymphoma of bone: long term results in patients treated with vincristine--adriamycin--cyclophosphamide and local radiation
    G Bacci
    Bone Tumor Center Istituto Rizzoli, Bologna, Italy
    J Chemother 3:189-93. 1991
    ..No local recurrences nor second tumor in the irradiated field were observed. We conclude that the addition of chemotherapy to radiotherapy results in an excellent cure rate for patients with PLB...
  76. ncbi Ewing's sarcoma of bone: relation between clinical characteristics and staging
    S Ferrari
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, I 40136 Bologna, Italy
    Oncol Rep 8:553-6. 2001
    ..Only six patients were positive for five factors and all of them had metastases at presentation. The parameters identified are clinical markers of Ewing's sarcoma having a particularly aggressive metastatic behavior...
  77. ncbi P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy
    N Baldini
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, University of Bologna, Italy
    J Orthop Res 17:629-32. 1999
    ..Standard programs are sufficient for P-glycoprotein-negative osteosarcomas, whereas P-glycoprotein-positive tumors may benefit from the use of more intensive therapeutic approaches...
  78. ncbi Local and systemic control in Ewing's sarcoma of the femur treated with chemotherapy, and locally by radiotherapy and/or surgery
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Bone Joint Surg Br 85:107-14. 2003
    ..Further studies are needed to verify the impact of this strategy on overall survival...
  79. ncbi Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity
    A Longhi
    Department of Musculoskeletal Oncology Istituto Ortopedico Rizzoli Bologna, Italy
    Cancer 89:1961-5. 2000
    ....
  80. ncbi Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response
    S Ferrari
    Chemioterapia, I Clinica Ortopedica dell Università di Bologna, Italy
    Tumori 85:458-64. 1999
    ..Additional aims were to assess the role of the route of infusion (intraarterial or intravenous) of cisplatin on histologic response of the primary tumor and the use of ifosfamide as salvage chemotherapy in poor responders...
  81. ncbi Brain tumors as second malignant neoplasms in patients with osteosarcoma treated with adjuvant and neoadjuvant chemotherapy: report of 2 cases
    A Longhi
    Department of Musculo Skeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 12:261-2. 2000
    ..They developed the brain tumor (one astrocytoma and one glioblastoma) 3 and 5 yr after treatment, (chemotherapy and surgery), for localized osteosarcoma of the extremity...
  82. ncbi Osteosarcoma in blood relatives
    A Longhi
    Service of Chemotherapy, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Oncol Rep 8:131-6. 2001
    ..These findings confirm that specific genetic alterations occur in osteosarcoma pathogenesis...
  83. ncbi Knee arthrodesis with a temporary spacer performed in malignant tumor around the knee
    D Donati
    1st Clinic of the University, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Arch Orthop Trauma Surg 122:123-8. 2002
    ..In our institution, reconstruction with cement is still suggested for patients with a large tumor around the knee, when the quadriceps is completely sacrificed, and the patient prognosis is markedly unfavorable...
  84. ncbi Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute
    S Ferrari
    Chemotherapy, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 12:1145-50. 2001
    ..To identify predictive factors of disease-free survival (DFS) in patients with non-metastatic osteosarcoma of the extremity, treated with primary chemotherapy and delayed surgery...
  85. ncbi Correlation between cystatin C and serum creatinine as markers of renal function in patients with neoplasms of the locomotor system
    C Zolezzi
    Laboratory of Medicine, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Chemother 13:316-23. 2001
    ..However, it is still premature to suppose that cystatin C can replace creatinine in routine tests. Establishing cystatin C levels can be useful in cases in which it is not possible to determine creatinine clearance...
  86. ncbi Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy
    A Longhi
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Chemother 16:582-8. 2004
    ..Protracted medical follow-up and long-term updated results are useful to identify, at an early stage, late relapses and late treatment-related complications...
  87. doi Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma
    S Ferrari
    Department Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Pediatr Blood Cancer 52:581-4. 2009
    ..To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT)...
  88. ncbi Neoadjuvant chemotherapy for localized Ewing's sarcoma of the extremities: preliminary results of a protocol which uses surgery (alone or followed by radiotherapy) for local control
    G Bacci
    Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 75:456-62. 1989
    ..These results indicate that after induction chemotherapy conservative surgery is possible in almost all cases of Ewing's sarcoma of the extremities and that such treatment is better than radiotherapy alone as local therapy...
  89. doi Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
    S Ferrari
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 22:1221-7. 2011
    ..High-dose chemotherapy (HDT) was added to conventional chemotherapy in Ewing sarcoma family tumor (EFT) patients, poor responders (PRs) to induction chemotherapy in order to improve their survival...
  90. ncbi Osteosarcoma of the pelvis
    D Donati
    Department of Musculoskeletal Oncology and Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Eur J Surg Oncol 30:332-40. 2004
    ..To describe the outcomes of a large number of patients with pelvic osteosarcoma, and to define the guidelines for appropriate treatment...
  91. ncbi Survival in high-grade osteosarcoma: improvement over 21 years at a single institution
    P Picci
    Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 21:1366-73. 2010
    ..Data are also analyzed in subgroups to define patients who benefited most...
  92. ncbi Surgery for lung metastases in Ewing's sarcoma of bone
    A Briccoli
    General Surgery, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Surg Oncol 30:63-7. 2004
    ..This study aims to report the results achieved in 24 Ewing's sarcoma patients who relapsed only with lung metastases, and no local recurrence, treated with surgery at the authors' institution...
  93. ncbi Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma
    S Ferrari
    Chemotherapy Unit, Instituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 21:205-10. 2009
    ..further investigations on sex-related susceptibility to chemotherapy in osteosarcoma patients are recommended...
  94. ncbi Pulmonary nodules in osteosarcoma patients: differential diagnosis of central venous catheter-related infections in the lungs
    A Longhi
    Sezione di Chemioterapia, Dipartimento di Oncologia Muscoloscheletrica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Radiol Med 111:192-201. 2006
    ..The purpose of this study was to evaluate the differential diagnosis of pulmonary nodules by conventional radiography and computed tomography (CT) in osteosarcoma patients with central venous catheter...
  95. ncbi Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma
    Stefano Ferrari
    Chemotherapy Service, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer 100:1936-42. 2004
    ..Investigation of the relation between primary tumor and metastatic disease is necessary for the identification of predictive factors for postrecurrence survival (PRS) in patients with recurrent osteosarcoma...
  96. doi Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger
    Massimo Eraldo Abate
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Pediatr Blood Cancer 55:652-4. 2010
    ..The occurrence of high-grade osteosarcoma is rare in children aged 5 years or younger and only limited series or case reports have been described...
  97. ncbi Local and distant control in non-metastatic pelvic Ewing's sarcoma patients
    Davide Donati
    Orthopaedic Surgery, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Surg Oncol 96:19-25. 2007
    ..The purpose of this study was to review our experience and evaluate the role of different local treatment in non-metastatic pelvic ES patients...
  98. ncbi Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study
    Stefano Ferrari
    Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 96:213-8. 2010
    ..To investigate a six-drug combination in patients with nonmetastatic Ewing sarcoma, focusing on chemotherapy-induced necrosis and chemotherapy toxicity in adult and pediatric patients...
  99. ncbi Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities
    Massimo Serra
    Laboratorio di Ricerca Oncologica, Sezione di Chemioterapia, Servizio di Anatomia Patologica, Va Divisione, and Unita di Chirurgia Generale, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Clin Oncol 21:536-42. 2003
    ..To evaluate the prognostic value of P-glycoprotein and clinicopathologic parameters in a large series of high-grade osteosarcoma (OS) patients treated at the Rizzoli Institute...
  100. ncbi Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma
    Alessandra Longhi
    Chemotherapy Division Rizzoli Orthopaedic Institute, St Orsola Malpighi University Hospital, Bologna, Italy
    Anticancer Drugs 18:737-44. 2007
    ..5% and five men=1.1%). Cumulative dose and dose intensity (cumulative dose/week of treatment) are the most important risk factors in developing doxorubicin-related cardiomyopathy...
  101. ncbi Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution
    Emanuela Palmerini
    Department of Chemotherapy, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 115:2988-98. 2009
    ..The optimal treatment for synovial sarcoma remains controversial. Treatment, outcome, and prognostic factors in patients treated in a single institution were examined...